Bafna Pharmaceuticals Reports Q2 EBITDA At ₹8.6 Crore With Margin Of 18.05%

Market snapshot: Bafna Pharmaceuticals reported strong operational profitability for Q2, marked by a doubling of its earnings before interest, taxes, depreciation, and amortization. Operating margin expanded significantly year-on-year, demonstrating operational efficiency.

Data Snapshot

• Q2 EBITDA reached ₹8.6 cr compared to ₹4.28 cr in the previous year.
• Q2 EBITDA margin expanded to 18.05% from 12.07% year-on-year.

What's Changed

• Operating profitability increased YoY, with EBITDA expanding 100.93% from ₹4.28 cr to ₹8.6 cr (derived: ₹8.6 cr vs ₹4.28 cr).
• EBITDA margin expanded by 598 bps from 12.07% to 18.05% year-on-year.

Key Takeaways

• Operating EBITDA expanded to ₹8.6 cr in Q2, doubling from ₹4.28 cr YoY.
• Operating margin reached 18.05%, up 5.98 percentage points from 12.07% in the year-ago period.
• Operational performance demonstrates efficiency gains across formulation operations.

SAHI Perspective

The sharp rise in EBITDA and operational margin highlights expanding profitability at Bafna Pharmaceuticals. Doubling core earnings with a near-600 bps margin expansion reflects disciplined expense management and a favorable product mix.

Market Implications

The positive earnings print strengthens operational metrics, providing headroom for internal accruals and investment into manufacturing capabilities.

Trading Signals

Market Bias: Bullish

Positive earnings trajectory supported by EBITDA doubling to ₹8.6 cr and margin widening 598 bps YoY to 18.05%.

Overweight: Pharmaceuticals, Contract Manufacturing

Trigger Factors:

• Sustained operating EBITDA margin above 18%
• Topline revenue growth continuity in subsequent quarters
• Active pharmaceutical ingredient input cost stability

Time Horizon: Near-term (0-3 months)

Industry Context

The Indian pharmaceutical formulation sector remains focused on high-margin products, process optimization, and export opportunities to sustain operational growth.

Key Risks to Watch

• Fluctuations in raw material prices affecting operating margins
• Regulatory compliance requirements across manufacturing facilities
• Competitive pricing in formulation markets

Recent Developments

Bafna Pharmaceuticals previously reported total operational revenue of ₹150.62 cr for FY26 with PAT rising to ₹11.10 cr, alongside a revision in its credit outlook to Positive (BB+/A4+) by ICRA.

Closing Insight

Bafna Pharmaceuticals' Q2 performance reflects significant operational leverage, laying a robust base for future financial stability.

High Performance Trading with SAHI.